Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels
- PMID: 17981115
- DOI: 10.1016/j.cell.2007.08.038
Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels
Abstract
Novel antiangiogenic strategies with complementary mechanisms are needed to maximize efficacy and minimize resistance to current angiogenesis inhibitors. We explored the therapeutic potential and mechanisms of alphaPlGF, an antibody against placental growth factor (PlGF), a VEGF homolog, which regulates the angiogenic switch in disease, but not in health. alphaPlGF inhibited growth and metastasis of various tumors, including those resistant to VEGF(R) inhibitors (VEGF(R)Is), and enhanced the efficacy of chemotherapy and VEGF(R)Is. alphaPlGF inhibited angiogenesis, lymphangiogenesis, and tumor cell motility. Distinct from VEGF(R)Is, alphaPlGF prevented infiltration of angiogenic macrophages and severe tumor hypoxia, and thus, did not switch on the angiogenic rescue program responsible for resistance to VEGF(R)Is. Moreover, it did not cause or enhance VEGF(R)I-related side effects. The efficacy and safety of alphaPlGF, its pleiotropic and complementary mechanism to VEGF(R)Is, and the negligible induction of an angiogenic rescue program suggest that alphaPlGF may constitute a novel approach for cancer treatment.
Comment in
-
alphaPlGF: a new kid on the antiangiogenesis block.Cell. 2007 Nov 2;131(3):443-5. doi: 10.1016/j.cell.2007.10.023. Cell. 2007. PMID: 17981110
Similar articles
-
alphaPlGF: a new kid on the antiangiogenesis block.Cell. 2007 Nov 2;131(3):443-5. doi: 10.1016/j.cell.2007.10.023. Cell. 2007. PMID: 17981110
-
PlGF blockade does not inhibit angiogenesis during primary tumor growth.Cell. 2010 Apr 2;141(1):166-77. doi: 10.1016/j.cell.2010.01.033. Cell. 2010. PMID: 20371352
-
Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation.Cancer Res. 2010 Aug 15;70(16):6537-47. doi: 10.1158/0008-5472.CAN-09-4092. Epub 2010 Aug 3. Cancer Res. 2010. PMID: 20682798
-
Tumor angiogenesis and anti-angiogenic therapies.Hum Antibodies. 2013;22(1-2):15-9. doi: 10.3233/HAB-130267. Hum Antibodies. 2013. PMID: 24284305 Review.
-
Tumor angiogenesis and anti-angiogenic therapy.Keio J Med. 2012;61(2):47-56. doi: 10.2302/kjm.61.47. Keio J Med. 2012. PMID: 22760023 Review.
Cited by
-
Compensatory angiogenesis and tumor refractoriness.Oncogenesis. 2015 Jun 1;4(6):e153. doi: 10.1038/oncsis.2015.14. Oncogenesis. 2015. PMID: 26029827 Free PMC article. Review.
-
Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO).Oncotarget. 2016 Nov 8;7(45):73984-73994. doi: 10.18632/oncotarget.12172. Oncotarget. 2016. PMID: 27659533 Free PMC article.
-
Targeting Intercellular Communication in the Bone Microenvironment to Prevent Disseminated Tumor Cell Escape from Dormancy and Bone Metastatic Tumor Growth.Int J Mol Sci. 2021 Mar 13;22(6):2911. doi: 10.3390/ijms22062911. Int J Mol Sci. 2021. PMID: 33805598 Free PMC article. Review.
-
Placental growth factor: What hematologists need to know.Blood Rev. 2017 Jan;31(1):57-62. doi: 10.1016/j.blre.2016.08.004. Epub 2016 Aug 27. Blood Rev. 2017. PMID: 27608972 Free PMC article. Review.
-
Chemotherapy in pediatric brain tumor and the challenge of the blood-brain barrier.Cancer Med. 2023 Dec;12(23):21075-21096. doi: 10.1002/cam4.6647. Epub 2023 Nov 23. Cancer Med. 2023. PMID: 37997517 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
